We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Read MoreHide Full Article
Key Takeaways
PBYI stock jumped 29.6% in three months, far outpacing its industry, sector and the S&P 500.
Nerlynx sales grew 9% in H1 2025 to $92.3M. Full-year sales are guided to be in the range of $192-$198M.
Initial phase II data on alisertib for lung cancer and breast cancer are expected in Q4 2025.
Puma Biotechnology (PBYI - Free Report) stock delivered a solid performance in the past three months, with its shares rallying 29.6% compared with the industry’s rise of 3.9%. The stock has also outperformed the sector and the S&P 500 index, as shown in the chart below.
Image Source: Zacks Investment Research
The key driver of the stock’s increase was better-than-expected results announced last month. Additionally, sales of Nerlynx, its sole marketed product, are improving and positive momentum is building around its pipeline. Let us delve deeper and take a closer look at Puma Biotechnology and how we should approach things.
Improving Nerlynx Sales Aid PBYI
Nerlynx (neratinib) is approved for treating early-stage HER2-positive breast cancer in patients previously treated with Roche’s (RHHBY - Free Report) Herceptin-based adjuvant therapy. Nerlynx is also approved in combination with Xeloda (capecitabine) for treating certain patients with advanced or metastatic HER2-positive breast cancer. The drug currently contributes the majority of PBYI’s revenues.
Nerlynx sales have been improving in the past couple of quarters. Sales of the drug rose 9% on a year-over-year basis to $92.3 million in the first six months of 2025. The company expects continued demand-driven growth in Nerlynx sales during the second half of 2025, which is likely to aid top-line growth.
Nerlynx product sales are expected to be in the range of $192-$198 million in 2025.
Alisertib - A Promising Pipeline Candidate for PBYI
Puma Biotechnology in-licensed the global development and commercialization rights to alisertib, an aurora kinase A inhibitor, from Japan’s Takeda in 2022. It is developing alisertib for hormone receptor-positive breast cancer as well as small-cell lung cancer (SCLC).
The company is conducting ALISCA-Lung1, a phase II study (PUMA-ALI-4201) evaluating alisertib as a monotherapy for the treatment of patients with extensive-stage SCLC. Interim data from this study are expected to be announced in the fourth quarter of 2025.
PBYI is also conducting a phase II ALISCA-Breast1 study on alisertib in combination with endocrine treatment for treating patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer. Initial data from the study is also expected in the fourth quarter of 2025.
Per management, if successfully developed, alisertib has the potential to boost the company’s position in the anticancer drug market and lower its heavy dependence on Nerlynx for revenues.
PBYI's Overdependence on Nerlynx & Competition in the Target Market
Puma Biotechnology has no approved product in its portfolio other than Nerlynx. As a result, the company remains heavily dependent on Nerlynx for revenues and overall growth.
While the breast cancer market holds immense commercial potential, Nerlynx faces intense competition in the targeted space. Established therapies include RHHBY's Herceptin and Novartis' Tykerb.
A few other companies are also developing treatments for extensive-stage SCLC. These dynamics create substantial challenges for the company, as alisertib, even if successfully developed, would likely encounter intense competition in its target market.
PBYI's Valuation & Estimates
From a valuation standpoint, Puma Biotechnology is trading at a discount to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 0.94, lower than 2.13 for the industry. The stock is trading above its five-year mean of 0.73.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved up from 65 cents to 66 cents over the past 60 days. During the same time frame, earnings per share estimates for 2026 have increased from 51 cents to 60 cents.
Image Source: Zacks Investment Research
Conclusion
Puma Biotechnology’s recent rally has been positive, given the improving sales performance of Nerlynx. The steady performance of Nerlynx, along with encouraging pipeline progress, should help the stock gain further momentum in 2025.
However, competition in the target remains a major concern. Any failure in ongoing studies and pipeline/regulatory setbacks will hurt growth prospects.
We advise a wait-and-watch stance for prospective investors as of now. Those who already own the stock can stay invested. Successful data readouts from its ongoing studies on alisertib will be an important catalyst for the stock.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share have moved up from $6.53 to $7.25. Earnings per share estimates for 2026 have increased from $7.07 to $7.74 during the same period. ANIP stock has soared 76.7% year to date.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for CorMedix’s 2025 earnings per share have moved up from $1.10 to $1.52. Earnings per share estimates for 2026 have increased from $1.46 to $2.12 during the same period. CRMD stock has surged 59.7% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 34.85%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Key Takeaways
Puma Biotechnology (PBYI - Free Report) stock delivered a solid performance in the past three months, with its shares rallying 29.6% compared with the industry’s rise of 3.9%. The stock has also outperformed the sector and the S&P 500 index, as shown in the chart below.
Image Source: Zacks Investment Research
The key driver of the stock’s increase was better-than-expected results announced last month. Additionally, sales of Nerlynx, its sole marketed product, are improving and positive momentum is building around its pipeline. Let us delve deeper and take a closer look at Puma Biotechnology and how we should approach things.
Improving Nerlynx Sales Aid PBYI
Nerlynx (neratinib) is approved for treating early-stage HER2-positive breast cancer in patients previously treated with Roche’s (RHHBY - Free Report) Herceptin-based adjuvant therapy. Nerlynx is also approved in combination with Xeloda (capecitabine) for treating certain patients with advanced or metastatic HER2-positive breast cancer. The drug currently contributes the majority of PBYI’s revenues.
Nerlynx sales have been improving in the past couple of quarters. Sales of the drug rose 9% on a year-over-year basis to $92.3 million in the first six months of 2025. The company expects continued demand-driven growth in Nerlynx sales during the second half of 2025, which is likely to aid top-line growth.
Nerlynx product sales are expected to be in the range of $192-$198 million in 2025.
Alisertib - A Promising Pipeline Candidate for PBYI
Puma Biotechnology in-licensed the global development and commercialization rights to alisertib, an aurora kinase A inhibitor, from Japan’s Takeda in 2022. It is developing alisertib for hormone receptor-positive breast cancer as well as small-cell lung cancer (SCLC).
The company is conducting ALISCA-Lung1, a phase II study (PUMA-ALI-4201) evaluating alisertib as a monotherapy for the treatment of patients with extensive-stage SCLC. Interim data from this study are expected to be announced in the fourth quarter of 2025.
PBYI is also conducting a phase II ALISCA-Breast1 study on alisertib in combination with endocrine treatment for treating patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer. Initial data from the study is also expected in the fourth quarter of 2025.
Per management, if successfully developed, alisertib has the potential to boost the company’s position in the anticancer drug market and lower its heavy dependence on Nerlynx for revenues.
PBYI's Overdependence on Nerlynx & Competition in the Target Market
Puma Biotechnology has no approved product in its portfolio other than Nerlynx. As a result, the company remains heavily dependent on Nerlynx for revenues and overall growth.
While the breast cancer market holds immense commercial potential, Nerlynx faces intense competition in the targeted space. Established therapies include RHHBY's Herceptin and Novartis' Tykerb.
A few other companies are also developing treatments for extensive-stage SCLC. These dynamics create substantial challenges for the company, as alisertib, even if successfully developed, would likely encounter intense competition in its target market.
PBYI's Valuation & Estimates
From a valuation standpoint, Puma Biotechnology is trading at a discount to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 0.94, lower than 2.13 for the industry. The stock is trading above its five-year mean of 0.73.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved up from 65 cents to 66 cents over the past 60 days. During the same time frame, earnings per share estimates for 2026 have increased from 51 cents to 60 cents.
Image Source: Zacks Investment Research
Conclusion
Puma Biotechnology’s recent rally has been positive, given the improving sales performance of Nerlynx. The steady performance of Nerlynx, along with encouraging pipeline progress, should help the stock gain further momentum in 2025.
However, competition in the target remains a major concern. Any failure in ongoing studies and pipeline/regulatory setbacks will hurt growth prospects.
We advise a wait-and-watch stance for prospective investors as of now. Those who already own the stock can stay invested. Successful data readouts from its ongoing studies on alisertib will be an important catalyst for the stock.
Puma Biotechnology, Inc. Price
Puma Biotechnology, Inc. price | Puma Biotechnology, Inc. Quote
PBYI's Zacks Rank & Stocks to Consider
Puma Biotechnology currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) and CorMedix (CRMD - Free Report) , each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share have moved up from $6.53 to $7.25. Earnings per share estimates for 2026 have increased from $7.07 to $7.74 during the same period. ANIP stock has soared 76.7% year to date.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for CorMedix’s 2025 earnings per share have moved up from $1.10 to $1.52. Earnings per share estimates for 2026 have increased from $1.46 to $2.12 during the same period. CRMD stock has surged 59.7% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 34.85%.